Merck
Tag details
Welcome to the 'Merck' tag page at Technorati. This page features content from the farthest reaches of the Blogosphere that authors have "tagged" with 'Merck'.
Look up
"Merck"
at The Free Dictionary
Latest blogosphere posts tagged “Merck”
-
Stocks That Are Better Than Gold
Pharmainfo.net —
Authority: 165
Stocks That Are Better Than Gold The Money Times - 35 minutes ago by Selena Maranjian - November 15, 2009 - 0 comments Stocks are tied to tangible things, too: actual bricks-and-mortar companies. Merck (NYSE: MRK) stock is tied to Merck buildings and Merck ... Advertisement: read more9 hours ago -
Article Title Unknown
Pharmainfo.net —
Authority: 165
Advertisement: read more1 day ago -
PhRMAs last two Chairmen
PharmaGossip —
Authority: 491
Story [IMG: http://1.bp.blogspot.com/_Se19XAPwVi8/Sv6AnE7YSCI/AAAAAAAAF1s/9UGKxsIPJA8/s400/birds+of+a+feather.jpg]1 day ago -
Article Title Unknown
Pharmainfo.net —
Authority: 165
Advertisement: read more1 day ago -
Merck (MRK) Drugs Under Scanner Of Cholesterol Study
Pharmainfo.net —
Authority: 165
Merck (MRK) Drugs Under Scanner Of Cholesterol Study Benzinga - 31 minutes ago Merck & Co., Inc. (NYSE: MRK) is likely to be impacted by a new cholesterol study that has its multibillion cholesterol medications under the scanner. Analysts are flying down to Orlando, Fla ... Advertisement: read more1 day ago -
Second Fosamax Lawsuit Trial Set to Begin January 12
AboutLawsuits.com —
Authority: 553
A firm trial date of January 12 has been scheduled for a Fosamax lawsuit against Merck & Co. over their popular osteoporosis drug, which alleges that the drug caused a woman to suffer severe and debilitating deterioration of the jaw, known as osteonecrosis of the jaw (ONJ) . The trial will be the second ...1 day ago -
Merck (MRK) Announces Completion of TRA 2˚P-TIMI 50 Clinical
Pharmainfo.net —
Authority: 165
Merck (MRK) Announces Completion of TRA 2˚P-TIMI 50 Clinical Advertisement: read more2 days ago -
Get A Refund If You Took Vytorin Or Zetia [Lawsuits]
Consumerist —
Authority: 777
If you or someone you know were prescribed the high cholesterol drugs Zetia or Vytorin and paid full price or a co-pay, you may be eligible for a refund as part of a recent class-action lawsuit. Manufacturers Merck and Schering-Plough are accused of violating consumer protection laws. While both drugs were marketed as ...2 days ago -
New Merck Begins Operations Worldwide
Pharmainfo.net —
Authority: 165
New Merck Begins Operations Worldwide Bernama - 22 minutes ago KUALA LUMPUR, Nov 13 (Bernama) -- Global healthcare leader Merck & Co has outlined its global strategy following the completion of its recent merger with Schering-Plough Corporation. The new Merck ... Advertisement: read more2 days ago -
A New Cholesterol Study Puts Focus on Merck Drugs
NYT > Theater —
Authority: 913
Researchers will present results with potentially significant implications for multibillion-dollar cholesterol medications from Merck.2 days ago -
(ENZN) Enzon Beats Expectations – Announces Sell-off
Stock Blog Hub —
Authority: 461
Enzon ( ENZN ) achieved break-even earnings during the third quarter of 2009, better than the Zacks Consensus Estimate of loss of 7 cents but below the year-ago earnings of 1 cent. The company reported revenues of $44.6 million, a decline of 9% compared to $48.8 million reported in the third quarter of 2008. Enzon ...3 days ago -
Opko Health Inc. Completes Acquisition of NK-1 Compounds from Merck & Co., Inc.s Schering Corporation
Pharmainfo.net —
Authority: 165
Opko Health Inc. Completes Acquisition of NK-1 Compounds from Merck & Co., Inc.s Schering Corporation Reuters Key Development - 1 hour ago Advertisement: read more4 days ago -
Wanted: A CEO For Merck… Who’ll Succeed Clark?
Pharmalot —
Authority: 596
Dick Clark turns 65 in March 2011, when a successor will have to be named. And ever since becoming Merck ceo in 2005, when his predecessor, Ray Gilmartin, stepped down in the wake of the Vioxx scandal, the low-key executive says his primary ojbective has been to ensure a successor is in place. And an announcement ...4 days ago -
Wall Street Ends Mostly Lower, Boeing (NYSE: BA) Tumbles
Pharmainfo.net —
Authority: 165
Wall Street Ends Mostly Lower, Boeing (NYSE: BA) Tumbles istockAnalyst.com - 37 minutes ago US stocks finished mixed on Tuesday as investors took a breather after Mondays sharp rally which pushed the Dow Jones industrial average to its highest level this year. The Dow Jones Industrial ... Advertisement: ...4 days ago -
Whytorin? Merck Cholesterol Pills Face Another Test
Pharmalot —
Authority: 596
The big drugmaker may encounter its third negative study result within two years for Vytorin and Zetia which, along with Zocor, is a component in the expensive cholesterol pill. The latest trial is scheduled to be presented this coming Monday at the American Heart Association meeting, and pits Merck’s drugs against ...5 days ago -
Merck Cholesterol Pill Sales May Drop 20% More on Study Finding
Pharmainfo.net —
Authority: 165
Merck Cholesterol Pill Sales May Drop 20% More on Study Finding Bloomberg - 42 minutes ago By Shannon Pettypiece Nov. 10 (Bloomberg) -- Merck & Co. may face a third negative study result within two years for its cholesterol pills Vytorin and Zetia, which have lost 14 percent of sales ... Advertisement: ...5 days ago -
(RX) Big Pharma and Biotech – Industry Outlook
Stock Blog Hub —
Authority: 461
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent ...5 days ago -
(SNTS) Santarus Incorporated Reports Strong Quarter
Stock Blog Hub —
Authority: 461
Santarus, Inc. ( SNTS ) reported third-quarter earnings of 9 cents per share, surpassing the Zacks Consensus Estimate at a loss of 1 cent and the year-ago loss of 8 cents. Total revenues, consisting of net product sales, promotion revenues, and license and royalty revenues, came in at $39.5 million, up 22% from the ...5 days ago -
The day ahead: Tuesday
From Reuters.com —
Authority: 127
At the Reuters Health Summit expect exclusive interviews with Merck CEO Richard Clark, AstraZeneca CEO David Brennan and Tenet CEO Trevor Fetter. Other highlights: * Treasury Secretary Timothy Geithner begins a two-day official visit to Japan ahead of the Asia-Pacific Economic Cooperation finance ministers’ ...5 days ago -
Januvia
AdPharm Blog —
Authority: 146
Click here to see it on AdPharm AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here .5 days ago